On the contrary, the presence of mutations in splicing factor genes (e.g, SRSF2, U2AF1) in addition to EZH2 and STAG2 is more indicative of high risk vs. low risk MDS. This evidence concerns the gene STAG2 and myelodysplastic syndrome.